Verona Pharma plc 2019 Annual Report And Accountsandnotice Of Agm

 
TIDMVRP 
 
   LONDON, March 16, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) 
(Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical 
company focused on developing and commercializing innovative therapies 
for respiratory diseases, is pleased to confirm that a hard copy of the 
Annual Report and Accounts for the year ended December 31, 2019 ("2019 
Annual Report and Accounts"), the Notice of Annual General Meeting and a 
Form of Proxy have been mailed to Shareholders of record as of March 13, 
2020. 
 
   Verona Pharma confirms that both the 
https://www.globenewswire.com/Tracker?data=AgxNI9U1Dsq0DQEK2wZLMiorOu9-oo-lzcmuCvPVJKrRnTXmZHNBItSFFvqm6LLnT6ue-bZvcVArI1exewcY-2NfFzB8cllfKO2a70EovkEXFjXKIKOJ9HVzOtABvUtW9lP5QLfZUUV2k5QNIGufU3ggpYb2d9d_dFK1zyQ_AlqWaR1tL3JPLTFwecmEAbw7hLd0D0-9G4yC_5AkxhVpPP0kgb_jTqBWfZkjqxCAp9s372fSz0X4aTgvBA3oXBoP 
2019 Annual Report and Accounts and 
https://www.globenewswire.com/Tracker?data=GxhMobjyf1U-d5CKnJgT_swwz8NKdv7fy_D6A7G5dQCijCBgVFgCBxoa6eb_OfX7c-kOPYKJ_wnN8RVPt79uBbvr2bTVwQaQt2jo6oMZXFGpiv_fbzwTYzR-nR-RA793-URrC-NNbCR6SYp9Qe3MvM5LauahAOMlQ69qPEIMbNmStbZRrQ1PZpMnVk09ZAHudK9AVfbU1mjUlK22l7KmuRRb2i9f49k0IEKNxfRgvlriOJECTyGII1afeYzOQcqa 
Notice of Annual General Meeting are available within the Investors 
section of its website, www.veronapharma.com. 
 
   The Annual General Meeting of Verona Pharma will be held at the offices 
of Shakespeare Martineau at 60 Gracechurch Street, London EC3V 0HR, 
United Kingdom at 10.30 a.m. on April 16, 2020. 
 
   About Verona Pharma 
 
   Verona Pharma is a clinical-stage biopharmaceutical company focused on 
developing and commercializing innovative therapies for the treatment of 
respiratory diseases with significant unmet medical needs. If 
successfully developed and approved, Verona Pharma's product candidate, 
ensifentrine, has the potential to be the first therapy for the 
treatment of respiratory diseases that combines bronchodilator and 
anti-inflammatory activities in one compound. Verona Pharma is currently 
in Phase 2 development with three formulations of ensifentrine for the 
treatment of COPD: nebulized, dry powder inhaler, and pressurized 
metered-dose inhaler. Ensifentrine also has potential applications in 
cystic fibrosis, asthma and other respiratory diseases. For more 
information, please visit www.veronapharma.com. 
 
   For further information, please contact: 
 
 
 
 
Verona Pharma plc                                      Tel: +44 (0)20 3283 4200 
-----------------------------------------------------  ------------------------- 
Victoria Stewart, Director of Communications           info@veronapharma.com 
-----------------------------------------------------  ------------------------- 
 
N+1 Singer                                             Tel: +44 (0)20 3283 4200 
-----------------------------------------------------  ------------------------- 
(Nominated Adviser and UK Broker) 
 Aubrey Powell / George Tzimas / Iqra Amin (Corporate 
 Finance) 
 Tom Salvesen (Corporate Broking) 
-----------------------------------------------------  ------------------------- 
 
Optimum Strategic Communications                       Tel: +44 (0)20 950 9144 
 (European Media and Investor Enquiries)                verona@optimumcomms.com 
-----------------------------------------------------  ------------------------- 
Mary Clark / Eva Haas / Hollie Vile 
-----------------------------------------------------  ------------------------- 
 
Argot Partners                                         Tel: +1 212-600-1902 
 (US Investor Enquiries)                                verona@argotpartners.com 
-----------------------------------------------------  ------------------------- 
Stephanie Marks / Kimberly Minarovich / Michael 
Barron 
-----------------------------------------------------  -------------------------
(END) Dow Jones Newswires
March 16, 2020 13:14 ET (17:14 GMT)
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024